Project Oncology®
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
- Update frequency
- every 5 days
- Episodes
- 347
- Years Active
- 2015 - 2025
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Guest: Shilpa Gupta, MD
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recom…
AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy
Guest: Anthony Stein, MD
Could a novel triplet combination therapy offer a new path forward in acute myeloid leukemia (AML) treatment? A recent …
AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy
Guest: Anthony Stein, MD
Could a novel triplet combination therapy offer a new path forward in acute myeloid leukemia (AML) treatment? A recent …
Reviewing the Latest Bladder Cancer Practice Guidelines
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immun…
Patient Perspectives on Bladder Cancer
Guest: Lillibeth Velasco, MSN, RN
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines…
Reviewing the Latest Bladder Cancer Practice Guidelines
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immun…
Patient Perspectives on Bladder Cancer
Guest: Lillibeth Velasco, MSN, RN
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines…
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immun…
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immun…
Chemotherapy Strategies for Metastatic PDAC
Guest: Shubham Pant, MD, MBBS
Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and h…
Diagnosis and Management of Metastatic PDAC
Guest: Shubham Pant, MD, MBBS
Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and h…
Chemotherapy Strategies for Metastatic PDAC
Guest: Shubham Pant, MD, MBBS
Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and h…
Diagnosis and Management of Metastatic PDAC
Guest: Shubham Pant, MD, MBBS
Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and h…
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
Guest: Matthew Matasar, MD
When treating relapsed or refractory large B-cell lymphoma (R/R LBCL) with CAR T-cell therapy, the risk of adverse ev…
Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sairah Ahmed, MD
Guest: Caron A. Jacobson, MD
The side effects associated with CAR T-cell therapy are very different than those seen …
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Guest: Julia Rotow, MD
In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, …
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Guest: Julia Rotow, MD
In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, …
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
Guest: Tara Graff, DO, MS
Host: Charles Turck, PharmD, BCPS, BCCCP
While CAR T-cell therapy is an effective option for patients with certain blood cancers like lymphoma and myeloma, it’…
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Guest: Laura Alder, MD
The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-li…
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Guest: Laura Alder, MD
The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-li…